
    
      Evaluation of progression-free survival, transplant related mortality, overall survival, and
      overall response rate, in subjects with NHL and HL receiving an IV busulfan-based
      conditioning regimen with PK-guided IV busulfan dosing, followed by autologous HSCT as well
      as comparison to those receiving carmustine, etoposide, cytarabine, and melphalan (BEAM)
      conditioning regimen (and its variants) obtained from registry data in the Center for
      International Blood and Marrow Transplant Research (CIBMTR) Assessment of the safety profile
      of a BuCyE conditioning regimen with PK-directed dosing of IV busulfan will also be
      completed.
    
  